INTRODUCTION
Cardiovascular diseases such as hypertension, valvular disease and myocardial infarction-induced ventricular dilation all impose a persistent, pathological increase in the work demands (afterload) of the heart [1] [2] [3] . Neurohumoral systems are activated to increase the contractile [Ca 2+ ] required to support the enhanced contractile demands of the diseased heart 4 . Over time, the persistently overworked left ventricle remodels, increasing wall thickness to at least partially compensate for increased wall stress 5 . This hypertrophy occurs at both the organ and cellular level, with an increase in left ventricular mass and an increase in cardiac myocyte size 6 . The signaling processes that produce pathological myocyte hypertrophy have essential Ca 2+ -dependent signaling steps, but there is some evidence that the sources of Ca 2+ for enhanced contractile function and for hypertrophic signaling are distinct [7] [8] [9] .
Hypertrophied myocytes adopt a modified electromechanical phenotype. The action potential (AP) is prolonged, Ca 2+ transients are disrupted with slower kinetics, sarcoplasmic reticulum (SR) Ca 2+ reuptake is slowed, Ca 2+ leak from the SR is increased to reduce SR Ca 2+ stores, and these systems become unresponsive to sympathetic regulation, reducing contractility reserve 10, 11 . Alterations in Ca 2+ regulation in hypertrophy is also linked to increased risk of arrhythmias and HF 12, 13 . Indeed, left ventricular hypertrophy (LVH) is an independent predictor of hospitalization and sudden cardiac death 14, 15 .
The molecular bases of altered contractile and hypertrophic signaling [Ca 2+ ] are still not fully understood and are the topic of this study 7 . Here, we specifically study the role of the SR protein, Stromal Interaction Molecule 1 (STIM1), and its sarcolemmal partner protein Orai in the development of electrical and contractile remodeling of adult ventricular myocytes after pressure overload. There is some evidence from previous reports that these proteins are present in cardiac myocytes and their abundance increases in disease states 16, 17 . This increase has been linked to maladaptive cardiac hypertrophy 18, 19 . However, the consequence of STIM-mediated Ca 2+ influx on the function of hypertrophied cardiac myocytes are not clearly defined, especially in large animals with Ca 2+ regulation similar to the human heart. In this study, we explore the idea that alterations in the electrical and mechanical properties of the hypertrophied heart involves STIM-dependent Ca 2+ entry and blocking this influx pathway can improve these disturbances.
STIM and Orai proteins are widely known as the key mediators of store operated Ca 2+ entry (SOCE), a nearly ubiquitous process in non-excitable cells 20, 21 . In mammals, there are two isoforms of STIM (STIM1 and STIM2) that are present in the endoplasmic reticulum (ER) 22 , and three homologs of Orai (Orai1, Orai2 and Orai3) located on the plasma membrane. SOCE occurs during periods of ER Ca 2+ depletion, which can physiologically occur after inositol triphosphate receptor activation of ER Ca 2+ release. STIM senses reduced ER [Ca 2+ ] via a luminal EF hand motif and subsequently undergoes a conformational change resulting in oligomerization 23 . Activated STIM proteins are then able to bind and gate Orai channels located in the plasma membrane, which are highly selective, low conductance Ca 2+ channels 24 . The resulting Ca with each heartbeat and is never depleted during normal physiological function. It is therefore not surprising that a physiological role for STIM and Orai in cardiac myocytes has not been defined. Yet, many independent groups have found STIM1 to be present in cardiac myocytes 27 , though there are conflicting reports on the function of STIM1 and SOCE in these cells 16, 28, 29 . In the diseased heart, SR Ca 2+ regulation is altered 11 and increased SOCE activity has been observed in rodent cardiac disease models. Some groups have linked this increased activity with pathological hypertrophy. A recent study 16 suggested that activated STIM1 can increase SR Ca 2+ loading by binding to phospholamban (PLB) and thereby regulating SERCA activity. This function of STIM1 in normal myocytes was found to be DOI: 10.1161/CIRCRESAHA.117.3110944 independent of Orai and SOCE. Collectively, these reports suggest that Ca 2+ influx through STIM and Orai proteins might be involved in the abnormal Ca 2+ regulation found in diseased ventricular myocytes. However, this hypothesis has not been tested in a clinically relevant large animal model.
The objective of our study was to explore the if/how STIM1 contributes to the changes in electrical and contractile phenotype of hypertrophied ventricular myocytes from the adult feline heart. We used the feline model because, unlike rodent models, it has electrical and Ca 2+ regulatory properties that are similar to those of human 30, 31 . Our experiments tested the hypothesis that in myocytes with hypertrophy from persistent pressure overload, SR based STIM1 is activated and partners with surface membrane Orai to produce Ca 2+ entry that contributes to their altered phenotype. Our results support the idea that STIM1 and Orai are expressed, but do not contribute to the electromechanical function of the healthy heart. In hypertrophied myocytes, STIM1 becomes activated and induces Ca 2+ entry after associating with Orai, resulting in enhanced SR loading and AP prolongation. Excessive STIM1-mediated Ca 2+ entry caused Ca 2+ sparks, spontaneous APs, and cell death. These results suggest that STIM1 activation in disease might help preserve SR Ca 2+ load but predisposes myocytes to arrhythmias and death.
METHODS
Methods are described in detail in the online data supplement. Briefly, LVH was induced in young cats by aortic banding, and myocytes were isolated using collagenase as described in detail previously. After isolation, Ca sparks and cell shortening were measured using standard techniques described in detail in previous reports from our group 28, 32 . Isolated myocytes from control and banded animals were exposed to 1 µmol/L BTP2 (N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide), in vitro, in cell physiology experiments. Myocytes were also studied in primary culture and infected with adenovirus overnight, as described previously 33 . Experiments with these myocytes were completed within 36 hours of isolation to minimize effects of culture-dependent phenotypic "drift" 34, 35 .
RESULTS

Pressure overload hypertrophy is associated with increased STIM1 expression and activity.
Slow progressive pressure overload was induced by aortic banding of young animals, to induce LVH, similar to our previous reports 36, 37 . This procedure caused significant increases in systolic proximal aortic pressure after 4 months (proximal vs distal pressure: 149.8±15.3 vs 87±9.6 mmHg, Figure 1A ) and a systolic pressure gradient of 63 mmHg across the aortic constriction. There are no significant decreases in ECHO-derived systolic function in this model ( Figure 1B ). End-diastolic wall thickness was significantly increased by banding as measured by echocardiography (Banded vs Sham: 7.5±0.5 vs 4.6±0.3 mm, p≤0.05, Figure 1C ). The heart weight to body weight (HW/BW) ratio was significantly increased in banded versus sham animals (9.2±1.13 vs 4.6±0.4, p≤0.01, Figure 1D) Pressure overload was associated with increases in the expression of SOCE-related mRNA. Real time polymerase chain reaction (RT-PCR) was used to measure mRNA levels of SOCE proteins in mRNA from isolated myocytes. Myocytes from banded animals had significantly greater amounts of STIM1 and Orai3 mRNA, and non-significant increases in STIM2 and Orai1 mRNA ( Figure 1E ). Orai2 was not detected in normal or hypertrophied feline myocytes.
Immunofluorescence staining of isolated myocytes showed that STIM1 exhibited a striated fashion in control myocytes ( Figure 1F, top) , with what appeared to be uniform intensity along the striations. Costaining with actinin suggests that STIM1 is localized near the Z-line, where the sarcolemma/SR dyad resides (Online Figure I, A) . This staining pattern is similar to that seen by others 16 . Hypertrophied myocytes from banded animals exhibited a more uneven STIM1 intensity, with a punctate pattern ( Figure 1F, bottom) . The mean fluorescence intensity of STIM1 staining was increased in banded animals ( Figure 1G ). STIM1 protein, measured by Western analysis, was also increased in hypertrophied versus normal hearts (Online Figure I, B) . Collectively, these studies show that STIM1 expression increases in feline ventricular myocytes with pressure overload-induced hypertrophy and suggest that STIM1 may oligomerize in these myocytes.
STIM1-Orai contributes to altered Ca
2+
handling in hypertrophied myocytes.
We have previously shown changes in contractile Ca 2+ regulation in the hypertrophied feline ventricular myocytes [38] [39] [40] which are consistent with the modifications in Ca 2+ handling observed by other laboratories 11, 41 . In the present study, we found that myocytes from banded animals had Ca phenotype is disturbed in pathological pressure overload induced hypertrophied feline myocytes 37, 38 .
The contribution of STIM1-Orai dependent Ca 2+ influx to steady state myocyte contractions and Ca 2+ transients was first explored by exposing isolated myocytes to the Orai blocker BTP2. This antagonist was chosen for its relative specificity for Orai over other ion channels 42 . Myocytes were incubated with either vehicle or BTP2, and then paced at 1Hz to measure steady state fractional shortening and Ca The effects of BTP2 on action potential duration (APD) in sham and hypertrophied myocytes were determined using the voltage sensitive dye di-8-anneps. This method is technically less demanding than patch clamp approaches and allowed for study of an increased number of myocytes. In addition, this approach allowed for evaluation of AP waveform, without dialysis that could eliminate distinct intracellular contents in hypertrophied myocytes. Preliminary studies showed APs had similar waveforms and durations when recorded using either di-8-anneps or patch-clamp in myocytes (not shown). BTP2 had no effect on APD in sham myocytes, with a time to 90% repolarization (APD90) of 285±9.5 ms (Figure 3 ). In contrast, myocytes from banded animals had longer baseline APDs and had significant APD shortening when incubated with BTP2, as compared to vehicle controls (APD90: 434±11 ms vs 390±11.5 ms for vehicle and BTP2 respectively. p≤0.01, Figure 3) . In separate experiments, we found that BTP2 did not reduce Ca To further explore the contribution of increased STIM1 expression to altered myocyte Ca 2+ regulation in disease, adenoviral gene transfer was used to express STIM1 (human cDNA clone) or red fluorescent protein (RFP) in freshly isolated adult feline myocytes (AFMs). Western blot and immunofluorescence confirmed increased expression of STIM1 within 12-18 hours of infection (Online Figure III) . In these studies, STIM1 was found to be organized into puncta, similar to the staining pattern seen in hypertrophied myocytes.
AFMs and other myocytes from large mammals are electrically and mechanically quiescent in primary culture, and they maintain low cytoplasmic and SR Ca 2+ 28, 43 . These properties result from the low cytoplasmic [Na + ] in large mammalian ventricular myocytes, which produces forward mode Na loading. However, previous studies suggest that STIM1 can also directly interact with the L-type calcium channel (LTCC) and modify its behavior 44, 45 , and this could alter myocyte Ca 2+ .
To test whether STIM1 interacted with LTCCs to alter SR loading, we exposed unpaced AFMs +/-STIM1 to verapamil, a potent LTCC blocker, and then induced SR Ca It has been recently suggested that one function of STIM1 in cardiac myocytes is to interact with phospholamban (PLB) to enhance the activity of SERCA. We attempted to replicate this interaction by coimmunoprecipitating STIM1 with PLB. No interaction between STIM1 and PLB was found. We did observe SERCA2a immunoprecipitate with PLB, as expected 46 (Online Figure V) . These results indicate that STIM1 does not interact with PLB in feline myocytes and suggest effects of STIM1 on Ca 2+ influx are due to its interaction with sarcolemmal Orai channels.
Increased STIM1 expression is sufficient to induce diastolic sparks.
STIM1 and RFP expressing myocytes were paced and diastolic Ca 2+ sparks and sarcomere length were measured. A very low rate of spark activity was observed in RFP control myocytes (Figures 5F and 5G). STIM1 myocytes exhibited increased spark rates and a greater reduction in diastolic sarcomere length ( Figure 5E ). These changes mirrored the increased spark activity and reduced sarcomere length seen during diastole in myocytes from banded animals ( Figure 4 ). BTP2 eliminated diastolic sparks in STIM1 myocytes ( Figure 5F ) but had no effects on RFP-infected myocytes (not shown), suggesting a role for STIM1-Orai dependent Ca 2+ influx.
To independently test a role for Orai in diastolic Ca
2+
sparks an Orai construct with a mutation in its pore forming region (E106Q), that blocks Ca 2+ permeation was employed 47 . This mutant will oligomerize with endogenous Orai channels (all isoforms), causing a dominant negative (dnOrai) effect, blocking all Orai channel activity 47 . AFMs were infected with dn-Orai that was tagged with RFP, along with STIM1. These experiments showed that STIM1 was co-localized with dn-Orai in a punctated pattern along the sarcolemma ( Figure 5H ). Co-expression of dn-Orai with STIM1 prevented the increased diastolic spark rate caused by STIM1 alone (Figures 5F and 5G). Collectively, these results suggest that Orai is a necessary partner for STIM1 to cause Ca 2+ influx in AFMs. release is known to induce NCX-mediated inward current which can be sufficient to depolarize the membrane potential and trigger an AP 41 . These experiments also show that Ad-STIM1 infected AFMs could have sufficient numbers of Ca 2+ sparks to elicit spontaneous APs ( Figure 6A ). Spontaneous Ca 2+ sparks were not blocked by verapamil, confirming that STIM1 does not raise myocyte Ca 2+ levels by altering the activity of LTCCs ( Figures 6D and 6E ). BTP2 and dn-Orai blocked resting sparks and spontaneous AP generation ( Figures 6D and 6E ).
STIM1-Orai Mediated Ca
STIM1 activation of Orai channels leads to CaMKII activation and cell death.
Our experiments showed that STIM1 expression increased the rate of AFM death after 72 hours (20-40% viability) versus RFP-infected controls (80-90% viability, Figures 7A and 7B ). We next explored the STIM1 membrane-signaling partner that is responsible for Ca 2+ influx and cell death signaling in STIM1 infected AFMs. Our group and others have previously documented the importance of canonical transient receptor potential channels (TRPC) mediated Ca 2+ influx in cell death signaling myocytes 28, 48 . Some reports suggest that STIM1 can bind to and activate TRPC channels and induce Ca 2+ influx 49 . Previous work in our laboratory demonstrated that expression of a dominant negative TRPC4 construct (dn-TRPC4) results in total inhibition of all TRPC activity, through its oligomerzation with each of the endogenous TRPC isoforms. 28 Using this same construct, we compared the effects of co-infection of STIM1 infected AFMs with either dn-TRPC4 28 or dnOrai. STIM1-induced cell death was not altered by dn-TRPC4 but was eliminated by dnOrai ( Figure 7B ). BTP2 also rescued the cell death phenotype of STIM1 myocytes ( Figure  7B ).
The link between increased Ca 2+ influx and cell death signaling has also been shown to involve the activation of Ca 2+ /calmodulin-dependent protein kinase II (CaMKII) 50 . To test this idea STIM1 or RFP infected myocytes were treated with KN-93, a CaMKII inhibitor. KN-93 rescued myocytes from cell death, though not as completely as with BTP2 ( Figure 7C ). Collectively, these results indicate that increased STIM1-mediated Ca 2+ entry can activate CaMKII, which likely contributes to both cell death and changes in myocyte Ca handling. Additional evidence for this idea was that phospholamban (PLB) phosphorylation at threonine 17 (Thr-17, a CaMKII specific site) was found to be increased in STIM1 myocytes ( Figure 7D ). PLB-Thr-17 phosphorylation also can explain the accelerated tau of Ca CaMKII activity has previously been shown to cause cell death by activating both apoptosis and necrosis in cardiac myoyctes. 51 To determine whether STIM1 causes apoptosis, caspase 3 cleavage was measured by Western analysis. No differences were found between STIM1 expressing myocytes and RFP controls (Online Figure VI) These results suggest that STIM1 activity can lead to necrotic cell death, similar to what we have seen when excess Ca 2+ influx through the LTCC is induced 33 .
DISCUSSION
SOCE and its effector proteins-STIM and Orai-are present in many tissue types where they regulate a number of different processes 23 . In noncardiac cells, SOCE is activated after ER Ca 2+ depletion and the resultant Ca 2+ influx refills the ER stores 23 . The presence and functional significance of SOCE in the normal adult heart is not well defined, but STIM expression in cardiac disease has been linked to pathological cardiac hypertrophy 27 . The goal of the present study was to determine if Ca 2+ influx through a STIM and Orai-dependent pathway contributes to the electromechanical phenotype of either normal or hypertrophied ventricular myocytes. A novel aspect of our study was that two independent approaches, pharmacologic (BTP2) Orai blockade and genetic (dnOrai) manipulation were used to demonstrate phenotypic features that were dependent on Orai channel function. Our experiments showed that both STIM1/2 and Orai1/3 are expressed in normal feline myocytes but are not major contributors to the phenotypic features we measured in this study (Online Figure II) . Therefore, their function in the normal heart is yet to be defined. STIM/Orai contributions to electromechanical remodeling in hypertrophied hearts were studied in ventricular myocytes isolated from feline hearts with slow, progressive pressure overload (aortic banding). Myocytes isolated from hypertrophied hearts exhibited increased STIM1 expression, similar to previous reports 29 . Our novel findings include the observation that STIM1 was organized into puncta, indicating STIM1 activation in hypertrophied myocytes ( Figure 1F ). Blockade of ion flux through STIM1/Orai with BTP2 in hypertrophied myocytes revealed, for the first time, that STIM1/Orai activity contributes to APD prolongation (Figure 3 ). In addition, we made the novel observation that STIM1-Orai activity leads to diastolic Ca 2+ sparks and a shortening of the diastolic sarcomere length (Figures 2 and 4) . Additional experiments with cultured adult feline myocytes (AFMs) showed that increasing STIM1 expression was sufficient to induce persistent Ca 
Expression and activity of STIM and Orai in normal cardiac myocytes.
The nature of SOCE in normal adult cardiac myocytes from a variety of species has been investigated by many laboratories and found to be very small or undetectable 16, 19, 27 . However, myocyte STIM1 knockout leads to aberrant cardiac structure and function
52
. Therefore, STIM1 clearly has roles that are yet to be defined. The experiments performed in the current study support the idea that STIM-Orai activity makes little or no contribution to the electromechanical function of normal ventricular myocytes. BTP2, a potent SOCE (Orai) blocker 23, 53 , did not modify APD, Ca 2+ transients or contractions of normal myocytes (Figures 2 and 3 and Online Figure II) . These data suggest that STIM and Orai proteins, while present in the normal heart, have little or no effects on Ca 2+ cycling. The reason(s) for the absence of detectable activation of STIM1-Orai in normal myocytes is unclear and requires additional study. For example, there is some evidence that STIM1 can be activated by ROS or pH changes, independent of the level of SR [Ca 2+ ] stores 25 and these issues were not examined. It is also possible that STIM and Orai have functional roles in the normal heart beyond the electromechanical features that we primarily examined.
STIM-Orai form a Ca
2+ Influx pathway that contributes to electromechanical remodeling in hypertrophy.
STIM1 expression increases after pressure overload 19, 27, 29 and the resultant Ca 2+ influx is thought to be involved in the induction of pathological hypertrophy. STIM1 may be part of the fetal gene program that becomes reactivated during pathological stress and could contribute a pool of Ca 2+ that activates pathological hypertrophy signaling. Reduction of STIM1 levels has been shown to reduce hypertrophic signaling in both neonatal and adult rodent myocytes 19, 27, 54 . Increased expression of STIM1 conversely resulted in an exaggerated hypertrophic response to TAC, MI, and chronic isoproterenol infusion in rodents 29 . Collectively, these studies support the idea that STIM1 expression and activity increase in myocytes responding to persistent pathological stress, and the resultant response includes myocyte hypertrophy.
The direct contribution of STIM1-Orai dependent Ca 2+ influx to the distinctive electromechanical phenotype of the hypertrophied ventricular myocytes has not been well studied and was the topic of this study. A feline model of slow progressive pressure overload that has critical features of human diseases, including concentric LV hypertrophy without systolic dysfunction (Figure 1 ) was employed. This model has many features of a human condition called heart failure with preserved ejection fraction (HFpEF) 55, 56 , with increases in ventricular wall thickness and HW/BW ( Figure 1C and 1D) without cardiac dilation or reductions in systolic function ( Figure 1B) . In myocytes from banded animals, STIM1 mRNA and protein was increased along with a small but significant increase in Orai3 mRNA ( Figure 1E ). It is possible that the Orai3 isoform is the major partner for STIM1 in cardiac disease, as found by others 17 . Future studies should focus on how the unique properties of Orai3 contribute to the electromechanical features of hypertrophied myocytes.
In myocytes from normal animals, immunofluorescence staining revealed that STIM1 is localized uniformly in the SR membrane along the Z-line (Online Figure I ) but in banded myocytes exhibited a punctated pattern ( Figure 1F ), indicative of STIM1 oligomerization 25 . These results support the idea that STIM1 is increased in abundance and activated in the hypertrophied heart.
A contractile role for STIM and Orai in hypertrophy.
Alterations in myocyte Ca
2+
handling are central to the development of the electromechanical phenotype of the diseased heart 11 . The idea that Ca 2+ entry through a STIM1-Orai complex contributes to phenotypic adaptation in disease has not, to our knowledge been studied in detail previously, especially in animal models with electromechanical properties similar to those in the human heart. To investigate whether increased STIM1-Orai activity contributes to contractile abnormalities in feline hypertrophy, we first employed BTP2 to block Orai channels. In comparison to other SOCE antagonists, BTP2 has little affinity for LTCCs 57 (Online Figure II, K) and potassium channels 42 . BTP2 had no effects on APs, Ca 2+ transients or contractions in normal myocytes, consistent with little or no STIM1-Orai activity in the normal heart and also documenting the lack of off target effects under the conditions we employed (Online Figure  II) . Figures 2, 3 and 4) . These changes result from modifications in the abundance and behavior of many molecules that participate in contraction 26 . To define a contribution of STIM1-Orai in these complex adaptations, hypertrophied AFMs were treated with BTP2. These studies showed that BTP2 shortened the APD, reduced diastolic spark rates and produced a lengthening of diastolic sarcomere length, but had no significant effects on steady state Ca 2+ transients ( Figures 2, 3 and 4) . A major advantage of using the feline model to explore STIM-Orai contributions to APD is the low membrane conductance during their human-like AP plateau phase 13 . The high conductance state during repolarization of rodent APs masks changes in small currents that could make important contributions to changes in APD in human disease 12, 13 .
Our results suggest that BTP2 blocks a small amount of Ca 2+ entry through a STIM-Orai channel complex in hypertrophied AFMs that contributes to APD prolongation in hypertrophied AFMs. Our results also suggest that this Ca 2+ influx can contribute to diastolic SR Ca 2+ leak (Ca 2+ sparks) that can reduce diastolic sarcomere length. Collectively, these data are consistent with the idea that increased STIM1/Orai activity in hypertrophy contributes to the electromechanical phenotype of hypertrophied AFMs.
STIM1/Orai regulate SR Ca
2+ .
Studies in genetically modified mice strongly support the idea that STIM1 expression is linked to cardiac hypertrophy 19 , likely through activation of SOCE. However, these studies do not directly link STIM1 to functional changes, since these could be secondary to the hypertrophy rather than directly resulting from STIM1 activity. To directly link the contributions of increased STIM1 expression/activity to myocyte electromechanical properties, we acutely expressed STIM1 in cultured AFMs. This model system allowed us to manipulate levels of STIM1 with minimal compensatory changes in global gene expression, which often occurs in genetic mouse models or in any model of induced disease. STIM1 was organized into puncta (Online Figure III ] within the diffusion limiting cleft between the T-tubule and SR membranes 41 or by altering the properties of ryanodine receptors, possibly by CaMKII-mediated phosphorylation, which we showed was increased in STIM1 myocytes. A recent study in cultured rodent ventricular myocytes suggests that expressed STIM1 interacts with phospholamban (PLB) to alter SR Ca 2+ uptake and induce SR Ca 2+ sparks 16 . We explored this possibility by examining the interaction between PLB and STIM1 using coimmunoprecipitation approaches (Online Figure V) , but could find no evidence to support this hypothesis.
STIM1 expression can cause AFM necrosis.
Our in-vitro studies show that STIM1 expression increased the rate of AFM death (Figure 7 ). STIM1 infected AFMs did not appear to die via apoptosis, suggestive of a necrotic process. We have previously found that persistent increases in Ca 2+ influx via the LTCC induces a necrotic cell death in genetically modified mice 58, 59 . The cell death effects of STIM1 were abolished by BTP2 and dnOrai, documenting a role for Ca 2+ influx via the STIM-Orai complex. Activation of CaMKII was also shown to be involved in this cell death effect ( Figure 7D and 7E) . These results warrant further exploration, as increased cell death in vivo would contribute to cardiac fibrosis and compensatory hypertrophy by the remaining myocytes, which may be partly responsible for the hypertrophy induced by STIM1 that others have observed 19 . In summary, the present study shows that pathological hypertrophy is associated with increases in STIM1 expression in AFMs. Our results are consistent with the idea that STIM1 associates with sarcolemmal Orai channels to produce Ca dependent arrhythmias and cell death in the diseased heart. Our findings suggest that STIM1-Orai activity increases in myocytes from hearts with disease-related increases in the contractile demands of the heart. Collectively, our findings suggest STIM-Orai mediated Ca 2+ influx directly contributes to both the induction of pathological hypertrophy as well as the aberrant electromechanical phenotype of the hypertrophied heart, making this complex an attractive therapeutic target.
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DISCLOSURES
Animal Model
Left ventricular hypertrophy was induced by methods described previously in detail 1, 2 . Briefly, a fixed size (2.8-3.0 mm in diameter) constricting band was placed around the ascending aorta of young male cats (~1.0 kg). Previously, we have shown that as animals grow they develop a concentric, compensated hypertrophy after 4 months. Non-invasive transthoracic echocardiography was performed at baseline and at 4 months after aortic constriction, using a ZONARE z.one ultra sp Ultrasound System. B-and m-mode loops were recorded from a right parasternal short axis view. Chamber geometry and wall thickness were measured. Fractional shortening was derived from m-mode images and expressed as [(diastolic chamber diametersystolic chamber diameter) / diastolic chamber diameter X 100%]. Hemodynamic studies were completed after 4 months of banding, using a RadiAnalyzer Xpress system that is used for fractional flow reserve (FFR) measurements in clinical routine to assess coronary physiology. Aortic pressures proximal and distal the band were recorded simultaneously using a pressure wire (Certus guidewire) and pressure gradients were calculated. The heart was then immediately excised, weighed and used for myocyte isolations. In total, four banded animals were used and 12 control animals were used for control experiments and for culture experiments.
Isolation and Culture of Feline Myocytes
Adult feline left ventricular myocytes (AFMs) were isolated as extensively described [3] [4] [5] [6] , with similar protocols used for both sham and banded animals. Briefly, felines were anesthetized with sodium pentobarbital and hearts were rapidly excised, cannulated, and mounted on a constant-flow Langendorff apparatus. Hearts were rinsed with a physiological Krebs-Henseleit buffer (KHB) containing (mmol/L): glucose 12.5, KCl 5.4, lactic acid 1, MgSO4 1.2, NaCl 130, NaH2PO4 1.2, NaHCO3 25, Na-pyruvate 2. Solutions were aerated with 95% oxygen and 5% carbon dioxide, pH 7.35 to 7.4, and warmed to 37C. Following the rinse step, hearts were retrograde perfused with collagenase-containing KHB (180 U/mL) supplemented with 50umol/L CaCl2. When the tissue softened, the left ventricle was isolated and gently minced, filtered, and equilibrated in KHB with 200 µmol/L CaCl2, and 1% bovine serum albumin (BSA) at room temperature. Isolated myocytes were washed with serum-free culture medium (Medium 199, Sigma) supplemented with penicillin-streptomycin-glutamine (PSG, Gibco). Myocytes were then used for physiologic measurements or cultured on plates or glass cover-slips coated with laminin (BD Bioscience). For long-term culture (>12hrs), cells were switched to Medium199/PSG with the addition of taurine (5mmol/L), creatine (5mmol/L), and carnitine (2mmol/L) (Sigma). Pacing experiments were done 18 hours after adenoviral infection, using an Ion Optix C-Pace system. Voltage and current was adjusted so >90% of myocytes were reliably paced in each culture dish.
Adenovirus
Ad-STIM1 encoding cDNA from human STIM1, was provided by Dr. Jonathan Soboloff. Ad-dnOrai was purchased from Vector BioLabs. It is a human Orai1 cDNA clone with an E106Q mutation which is located in the pore-forming region of Orai1. Additionally, an RFP tag was placed on the C-terminus. A multiplicity of infection (MOI) of 100 was used for each virus.
Western Blot
Whole cell lysates were prepared from isolated feline myocytes and analyzed by Western as previously described [7] [8] [9] [10] , and imaged with a Licor Odyssey Scanner, then analyzed with Image Studio (Li-Cor Biosciences). The following primary antibodies were used for detection: STIM1 (Cell Signaling), total phospholamban (Millipore), phospho-phospholamban (PLB Thr-17, Badrilla Ltd.), calcium/calmodulin kinase II delta (Badrilla Ltd.), calcium/calmodulin kinase II pThr286/287 (Badrilla Ltd.), Caspase (Cell Signaling), Activated Caspase (Cell Signaling). For a positive control in apoptosis and activated caspase experiments, lysates treated with cytochrome C were used (Cell Signaling).
Immunofluorescence Staining
AFMs were placed on laminin coated glass coverslips then washed 1X with PBS and fixed with cold 4% paraformaldehyde for 20 minutes. Cells were permeabilized with PBS containing 1% Triton X-100 and blocked with 1% bovine serum albumin in PBS for 30 minutes. Cells were then incubated overnight at 4° C with primary antibody (1:100), followed by the secondary antibody for 1 hour at 37° C. FITC donkey anti-rabbit IgG, rhodamine red-X donkey anti-mouse IgG, Alexa-647 donkey anti-mouse IgG secondaries were used (Jackson Immunoresearch Laboratories). Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI, Millipore). Coverslips were mounted on glass slides with VECTASHIELD HardSet Mounting Medium (Vector Labs). Confocal micrographs were acquired using a Nikon Eclipse T2 confocal microscope (Nikon Inc). Image brightness and contrast were adjusted for visibility in figures using ImageJ (NIH), but identical adjustments were made between groups. ImageJ (NIH) was used to calculate average myocyte staining intensity with 45 myocytes from three banded and three sham animals. Primary antibodies were wheat germ agglutinin-FITC, Rabbit STIM1 (Protein Tech), and mouse actinin (Sigma).
RT-PCR
Total RNA was extracted from snap-frozen isolated left ventricular myocytes utilizing TRIzol Reagent (Life Technologies) and cDNA was obtained from 500ng total RNA using SuperScript ® III First strand kit (Invitrogen). Real-time RT-PCR was performed using primers listed below. To avoid the influence of genomic contamination, forward and reverse primers for each gene were located in different exons. The StepOnePlus Real-Time PCR system (Applied Biosystems) was employed for quantitative RT-PCR. In each case, cDNA and primers were combined with QuantiFast SYBR Green (Qiagen). Cycling conditions were as follow: 95°C for 10 min followed by 40 cycles of amplification (95°C denaturation for 15 sec, 60°C annealing and extension for 1 min). Melting curves were then obtained. Ct values were normalized with respect to GAPDH. Data are expressed as fold change (2^-ΔΔCT method). Primers used are listed below: 
